Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.

@article{Clemons2006PhaseIT,
  title={Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.},
  author={Mark Clemons and George Dranitsaris and Wei Siong Ooi and Geetha Yogendran and Tatjana Sukovic and Betty Y. L. Wong and Sunil Verma and Kathleen I. Pritchard and Maureen Trudeau and David E. C. Cole},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 30},
  pages={4895-900}
}
PURPOSE This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate. PATIENTS AND METHODS This prospective study evaluated the impact of second-line zoledronic acid on pain, quality of life, and markers of bone turnover (for… CONTINUE READING